Goldman Sachs
AQST icon

Goldman Sachs’s Aquestive Therapeutics AQST Stock Holding History

Goldman Sachs’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Buy
468,569
+1,802
+0.4% +$7.58K ﹤0.01% 4702
2026
Q1 		$1.94M Sell
466,767
-442,297
-49% -$1.8M ﹤0.01% 4569
2025
Q4 		$5.87M Buy
909,064
+513,914
+130% +$3.2M ﹤0.01% 3600
2025
Q3 		$2.21M Sell
395,150
-129,535
-25% -$560K ﹤0.01% 4385
2025
Q2 		$1.74M Sell
524,685
-294,164
-36% -$844K ﹤0.01% 4288
2025
Q1 		$2.37M Sell
818,849
-57,688
-7% -$175K ﹤0.01% 4005
2024
Q4 		$3.12M Buy
876,537
+653,850
+294% +$3.02M ﹤0.01% 3917
2024
Q3 		$1.11M Buy
222,687
+108,678
+95% +$423K ﹤0.01% 4565
2024
Q2 		$296K Sell
114,009
-412,413
-78% -$1.38M ﹤0.01% 5111
2024
Q1 		$2.24M Buy
526,422
+495,923
+1,626% +$1.65M ﹤0.01% 3783
2023
Q4 		$61.6K Buy
+30,499
New +$53.9K ﹤0.01% 5355
2023
Q3 		– Sell
-57,149
Closed -$94.3K – 5526
2023
Q2 		$94.3K Buy
+57,149
New +$103K ﹤0.01% 5366
2022
Q4 		– Sell
-27,704
Closed -$32K – 5970
2022
Q3 		$32K Buy
27,704
+13,545
+96% +$15.3K ﹤0.01% 5849
2022
Q2 		$9K Sell
14,159
-34,153
-71% -$45.4K ﹤0.01% 6281
2022
Q1 		$126K Sell
48,312
-8,995
-16% -$26.3K ﹤0.01% 6032
2021
Q4 		$223K Sell
57,307
-15,858
-22% -$79.6K ﹤0.01% 5833
2021
Q3 		$319K Buy
73,165
+5,135
+8% +$20.1K ﹤0.01% 5458
2021
Q2 		$270K Buy
68,030
+21,204
+45% +$84.7K ﹤0.01% 5577
2021
Q1 		$243K Sell
46,826
-4,341
-8% -$23.1K ﹤0.01% 5546
2020
Q4 		$274K Sell
51,167
-29,160
-36% -$175K ﹤0.01% 4933
2020
Q3 		$390K Buy
80,327
+60,476
+305% +$395K ﹤0.01% 4608
2020
Q2 		$96K Buy
+19,851
New +$91.4K ﹤0.01% 5001
2020
Q1 		– Sell
-48,336
Closed -$281K – 5196
2019
Q4 		$281K Buy
48,336
+38,127
+373% +$198K ﹤0.01% 4777
2019
Q3 		$32K Buy
+10,209
New +$38.3K ﹤0.01% 5080
2019
Q2 		– Sell
-40,160
Closed -$278K – 5112
2019
Q1 		$278K Buy
40,160
+19,265
+92% +$135K ﹤0.01% 4664
2018
Q4 		$132K Sell
20,895
-559
-3% -$7.06K ﹤0.01% 4945
2018
Q3 		$376K Buy
+21,454
New +$354K ﹤0.01% 4575

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Goldman Sachs's AQST Position: Q2 2026 in Review

Goldman Sachs increased its Aquestive Therapeutics (AQST) stake by 0.39% in Q2 2026, buying an estimated $7.58K and bringing the position to 468,569 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #4702.

Goldman Sachs first reported a position in AQST in Q3 2018 and has held it in 27 quarters since. The position peaked at $5.87M in Q4 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Goldman Sachs held 468,569 shares of Aquestive Therapeutics worth $1.95M as of Q2 2026.
  • Goldman Sachs bought 1,802 Aquestive Therapeutics shares in Q2 2026, an estimated $7.58K.
  • Aquestive Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4702 holding.
  • Goldman Sachs first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 27 quarters since.
  • Goldman Sachs's Aquestive Therapeutics position peaked at $5.87M in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.